pyrazines has been researched along with Alzheimer Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Q; Huang, G; Li, W; Li, Z; Liu, W; Ma, G; Meng, X; Wang, S; Zhang, Y | 1 |
| Chen, H; Cheng, J; Guo, B; Huang, C; Su, Z; Sun, Y; Wang, Y; Wu, J; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhu, Z | 1 |
| Huang, S; Huang, Z; Liu, T; Weng, G; Zhou, B | 1 |
| Jiang, SJ; Liu, J; Qin, XH; Wang, J; Wang, LX; Zhang, Q; Zhu, L | 1 |
| Li, W; Li, X; Liang, X; Lu, F; Wei, K; Yao, Y; Zhang, J; Zhang, Q | 1 |
| Elkamhawy, A; Hassan, AHE; Lee, J; Pae, AN; Park, BG; Park, JE; Roh, EJ | 1 |
| Feng, X; Hong, G; Li, G; Li, X; Liu, T; Mao, L; Xu, Z; Zhang, Y | 1 |
| Amjad, MW; Bukhari, SNA; Hussain, MA; Leng, J; Qin, HL; Raja, MAG; Wang, M | 1 |
| Elkamhawy, A; Hassan, AHE; Lee, J; Pae, AN; Paik, S; Park, BG; Park, JE; Roh, EJ | 1 |
| Cheng, Y; Dai, J; Fu, Y; Jiang, Q; Li, G; Li, Y; Qi, Q; Zhang, T; Zhu, B | 1 |
| Dolezal, M; Zitko, J | 1 |
| Alharthy, RD; Bajorath, J; Furtmann, N; Hameed, A; Iqbal, J; Khan, KM; Shah, SJ; Tahir, MN; Zehra, ST | 1 |
| Cai, W; Chen, HY; Cui, W; Han, YF; Long, C; Sun, YW; Tan, GL; Tsim, KW; Wang, JZ; Wang, YQ; Xu, DP; Yu, P; Zhang, GX; Zhang, ZJ | 1 |
| Abbatecola, AM; D'Amico, M; Di Filippo, C; Ferraraccio, F; Marfella, R; Paolisso, G; Rossi, F | 1 |
| Cong, W; Liu, Q; Luo, G; Shi, J; Wang, Y | 1 |
| Huh, JW; Jang, M; Kim, DH; Kim, TW; Park, JS; Suh, JH; Yoon, SY | 1 |
| Luo, G; Shi, J; Wang, Y | 1 |
| Berg, S; Bergh, M; Bhat, R; Hellberg, S; Högdin, K; Jerning, E; Lo-Alfredsson, Y; Neelissen, J; Nilsson, Y; Ormö, M; Söderman, P; Tucker, J; von Berg, S; Weigelt, T; Xue, Y | 1 |
| Bauer, S; Berger, R; Bittner, T; Boländer, A; Burgold, S; Czech, C; Goetschy, V; Herms, J; Heyny-von Haußen, R; Hilger, I; Hölzer, J; Kieser, D; Knust, H; Mall, G; Schmidt, B; Schön, C; Voss, C | 1 |
| Durrance, A | 1 |
| Cai, J; Cui, X; Wang, SZ; Zhang, C; Zuo, PP | 1 |
| Gharibzadeh, S; Hoseini, SS; Mahdavi, S | 1 |
| Auguet, M; Chabrier, PE; Demerlé-Pallardy, C | 1 |
2 review(s) available for pyrazines and Alzheimer Disease
| Article | Year |
|---|---|
Pyrazine derivatives: a patent review (June 2012 - present).
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Cell Proliferation; Drug Design; Drug Industry; Humans; Molecular Structure; Neuroprotective Agents; Patents as Topic; Protein Kinase Inhibitors; Pyrazines; Structure-Activity Relationship | 2015 |
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; Brain Ischemia; Enzyme Induction; Humans; Huntington Disease; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Nerve Degeneration; Nerve Tissue Proteins; Nervous System Diseases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Organ Specificity; Polymethacrylic Acids; Pyrazines; Thiophenes | 1999 |
21 other study(ies) available for pyrazines and Alzheimer Disease
| Article | Year |
|---|---|
Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Luciferases; Mice; Mice, Transgenic; Mitophagy; Piperazine; PPAR gamma; Presenilin-1; Protein Kinases; Pyrazines; Rats; Sequestosome-1 Protein; Ubiquitin-Protein Ligases | 2022 |
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Avoidance Learning; Cognition Disorders; Disease Models, Animal; Donepezil; Drug Evaluation, Preclinical; Hydrazones; MAP Kinase Signaling System; Memantine; Mice; Mice, Transgenic; Morris Water Maze Test; Neuroprotective Agents; Phosphorylation; Protein Processing, Post-Translational; Pyrazines; Random Allocation; Recognition, Psychology; Signal Transduction; tau Proteins; TOR Serine-Threonine Kinases | 2021 |
Tetramethylpyrazine Improves Cognitive Function of Alzheimer's Disease Mice by Regulating SSTR4 Ubiquitination.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Rats; Receptors, Somatostatin; Tumor Cells, Cultured; Ubiquitination | 2021 |
Ligustrazine Attenuates Hyperhomocysteinemia-induced Alzheimer-like Pathologies in Rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Hippocampus; Humans; Hyperhomocysteinemia; Memory Disorders; Neurons; Neuroprotective Agents; Phosphorylation; Pyrazines; Rats; Rats, Sprague-Dawley | 2021 |
Tetramethylpyrazine reverses intracerebroventricular streptozotocin-induced memory deficits by inhibiting GSK-3β.
Topics: Alzheimer Disease; Animals; Glycogen Synthase Kinase 3; Hippocampus; Injections, Intraventricular; Learning; Male; Memory; Memory Disorders; Neurons; Neuroprotective Agents; Pyrazines; Rats, Wistar; Streptozocin | 2017 |
Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Death; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Molecular Docking Simulation; Molecular Structure; Pyrazines; Pyridines; Structure-Activity Relationship | 2018 |
Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cholinesterase Inhibitors; Humans; Hydroxybenzoates; Models, Molecular; PC12 Cells; Pyrazines; Rats; Tacrine | 2018 |
Synthesis and biological evaluation of new tetramethylpyrazine-based chalcone derivatives as potential anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Survival; Chalcones; Drug Design; Humans; Inhibitory Concentration 50; Monoamine Oxidase; PC12 Cells; Protective Agents; Pyrazines; Rats; Structure-Activity Relationship | 2018 |
Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Hippocampus; Humans; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Models, Molecular; Molecular Structure; Neural Stem Cells; Neuroprotective Agents; Pyrazines; Structure-Activity Relationship; Urea | 2018 |
Synthesis and evaluation of pyrazine and quinoxaline fluorophores for in vivo detection of cerebral tau tangles in Alzheimer's models.
Topics: Aged; Alzheimer Disease; Animals; Brain; Cell Line, Tumor; Fluorescent Dyes; Humans; Male; Mice, Transgenic; Optical Imaging; Pyrazines; Quinoxalines; tau Proteins | 2018 |
Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Pyrazines; Structure-Activity Relationship | 2015 |
A Potent Multi-functional Neuroprotective Derivative of Tetramethylpyrazine.
Topics: Alzheimer Disease; Animals; Antioxidants; Cells, Cultured; Hydrazones; Mice; Neurons; Neuroprotective Agents; PC12 Cells; Pyrazines; Rats; Rats, Sprague-Dawley | 2015 |
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Memory Disorders; Mice; Mice, Transgenic; Motor Activity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease.
Topics: Administration, Cutaneous; Alkaloids; Alzheimer Disease; Animals; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Therapy, Combination; Emulsions; Male; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Skin Absorption; Time Factors; Transdermal Patch; Vasodilator Agents | 2012 |
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.
Topics: Alzheimer Disease; Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Male; Neurons; Phosphorylation; Primary Cell Culture; Pyrazines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Sitagliptin Phosphate; tau Proteins; Triazoles | 2012 |
Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease, in vitro and in animal model studies.
Topics: Acrylic Resins; Administration, Cutaneous; Alzheimer Disease; Amnesia; Animals; Antioxidants; Behavior, Animal; Brain; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Escape Reaction; Ethanol; Glutathione Peroxidase; Lipid Peroxidation; Male; Malondialdehyde; Memory; Mice; Mice, Inbred ICR; Mice, Nude; Microscopy, Confocal; Permeability; Phosphatidylcholines; Pyrazines; Rats; Rats, Sprague-Dawley; Reaction Time; Scopolamine; Skin; Skin Absorption; Superoxide Dismutase; Technology, Pharmaceutical; Time Factors | 2012 |
Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.
Topics: 3T3 Cells; Alzheimer Disease; Animals; Blood-Brain Barrier; Caco-2 Cells; Cattle; Crystallography, X-Ray; Drug Design; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Models, Molecular; Molecular Structure; Permeability; Phosphorylation; Pyrazines; Solubility; Sulfonamides; tau Proteins | 2012 |
Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease models.
Topics: Aged, 80 and over; Alzheimer Disease; Animals; Biological Availability; Brain; Fluorescent Dyes; Humans; Mice; Mice, Transgenic; Microscopy, Fluorescence; Olfactory Mucosa; Organ Specificity; Permeability; Plaque, Amyloid; Pyrazines; Pyridazines; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; tau Proteins | 2012 |
Proteinase inhibitors - IBC's Third International Conference. New approaches, new discoveries, new targets.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Boronic Acids; Bortezomib; Cathepsins; Drug Evaluation, Preclinical; Endopeptidases; Humans; Inflammation; Peptide Library; Protease Inhibitors; Pyrazines | 2004 |
Protective effect of tetramethylpyrazine on learning and memory function in D-galactose-lesioned mice.
Topics: Alzheimer Disease; Animals; Galactose; Hippocampus; Male; Maze Learning; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Pyrazines; Receptors, Muscarinic | 2004 |
Oltipraz may be useful in the prevention or treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Humans; Mice; Neurodegenerative Diseases; Oxidative Stress; Pyrazines; Schistosomicides; Thiones; Thiophenes | 2007 |